Results From ECHELON-2: Brentuximab Vedotin in CD30-Expressing Peripheral T-Cell Lymphoma
The phase III ECHELON-2 clinical trial has met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) with brentuximab vedotin (Adcetris) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL).
ECHELON-2 is a global, randomized, double-blind, multicenter trial evaluating brentuxiamb vedotin as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-expressing PTCL, also known as mature T-cell lymphoma (MTCL). Brentuximab vedotin is an antibody-drug conjugate directed to CD30, which is expressed on the surface of several types of PTCL. Brentuximab vedotin is currently not approved for the frontline treatment of PTCL.
ECHELON-2 Methods and Results
Patients in ECHELON-2 were randomized to receive either a combination of brentuximab vedotin plus CHP or CHOP, a recognized standard of care for frontline PTCL. Results from the trial demonstrated that combination treatment with brentuximab vedotin plus CHP was superior to the control arm for PFS as assessed by an Independent Review Facility (hazard ratio [HR] = 0.71; P = .0110). The brentuximab vedotin plus CHP arm also demonstrated superior overall survival (OS), a key secondary endpoint, compared to CHOP (HR = 0.66; P = .0244). All other key secondary endpoints, including PFS in patients with systemic anaplastic large cell lymphoma, complete remission rate, and objective response rate, were statistically significant in favor of the brentuximab vedotin plus CHP arm.
The safety profile of brentuximab vedotin plus CHP in the ECHELON-2 trial was comparable to CHOP and consistent with the established safety profile of brentuximab vedotin in combination with chemotherapy.
Additional data will be presented at the American Society of Hematology 2018 Annual Meeting, to be held December 1 to 4, 2018, in San Diego.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
